Prognostic Significance of MiRNA-1 (miR-1) Expression in Patients with Chordoma

Overview

Journal J Orthop Res

Publisher Wiley

Specialty Orthopedics

Date 2014 Feb 7

PMID 24501096

Citations 24

Authors

Zhenfeng Duan

Jacson Shen

Xiaoqian Yang

Pei Yang

Eiji Osaka

Edwin Choy

Gregory Cote

David Harmon

Yu Zhang

G Petur Nielsen

Dimitrios Spentzos

Henry Mankin

Francis Hornicek

Affiliations

Soon will be listed here.

Abstract

Reliable prognostic biomarkers for chordoma have not yet been established. Recent studies revealed that expression of miRNA-1 (miR-1) is frequently downregulated in several cancer types including chordoma. The goal of this follow-up study is to investigate the expression of miR-1 as a prognostic biomarker and further confirm the functional role of miR-1 in chordoma cell growth and proliferation. We determined the relative expression levels of miR-1 and Met in chordoma tissue samples and correlated those to clinical variables. The results showed that miR-1 was downregulated in 93.7% of chordoma tissues and expression was inversely correlated with Met expression. miR-1 expression levels also correlated with clinical prognosis. To characterize and confirm the functional role of miR-1 in the growth and proliferation of chordoma cells, miR-1 precursors were stably transfected into chordoma cell lines UCH-1 and CH-22. Cell Proliferation Assay and MTT were used to evaluate cell growth and proliferation. Restoring expression of miR-1 precursor decreased cell growth and proliferation in UCH-1 and CH-22 cells. These results indicate that suppressed miR-1 expression in chordoma may in part be a driver for tumor growth, and that miR-1 has potential to serve as prognostic biomarker and therapeutic target for chordoma patients.

Citing Articles

Identification of miR-1 and miR-499 in chronic atrial fibrillation by bioinformatics analysis and experimental validation.

Chen X, Zhang Y, Meng H, Chen G, Ma Y, Li J Front Cardiovasc Med. 2024; 11:1400643.

PMID: 39221422 PMC: 11361948. DOI: 10.3389/fcvm.2024.1400643.

Function and regulation of miR-186-5p, miR-125b-5p and miR-1260a in chordoma.

Huo X, Wang K, Yao B, Song L, Li Z, He W BMC Cancer. 2023; 23(1):1152.

PMID: 38012562 PMC: 10680222. DOI: 10.1186/s12885-023-11238-x.

Prognostic molecular biomarkers in chordomas: A systematic review and identification of clinically usable biomarker panels.

Rubino F, Alvarez-Breckenridge C, Akdemir K, Conley A, Bishop A, Wang W Front Oncol. 2022; 12:997506.

PMID: 36248987 PMC: 9557284. DOI: 10.3389/fonc.2022.997506.

Potential molecular mechanism in self-renewal is associated with miRNA dysregulation in sacral chordoma - A next-generation RNA sequencing study.

Bozsodi A, Scholtz B, Papp G, Sapi Z, Biczo A, Varga P Heliyon. 2022; 8(8):e10227.

PMID: 36033338 PMC: 9404356. DOI: 10.1016/j.heliyon.2022.e10227.

MiR-17 and miR-93 Promote Tumor Progression by Targeting p21 in Patients with Chordoma.

Dong W, Li J, Dong X, Shi W, Zhang Y, Liu Y Onco Targets Ther. 2021; 14:3109-3118.

PMID: 34054299 PMC: 8153071. DOI: 10.2147/OTT.S307138.

References

Bydon M, Papadimitriou K, Witham T, Wolinsky J, Bydon A, Sciubba D . Novel therapeutic targets in chordoma. Expert Opin Ther Targets. 2012; 16(11):1139-43. DOI: 10.1517/14728222.2012.714772. View

Scheil S, Bruderlein S, Liehr T, STARKE H, Herms J, Schulte M . Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1. Genes Chromosomes Cancer. 2001; 32(3):203-11. DOI: 10.1002/gcc.1184. View

Duan Z, Choy E, Nielsen G, Rosenberg A, Iafrate J, Yang C . Differential expression of microRNA (miRNA) in chordoma reveals a role for miRNA-1 in Met expression. J Orthop Res. 2009; 28(6):746-52. DOI: 10.1002/jor.21055. View

Kong Y, Ferland-McCollough D, Jackson T, Bushell M . microRNAs in cancer management. Lancet Oncol. 2012; 13(6):e249-58. DOI: 10.1016/S1470-2045(12)70073-6. View

Palmieri A, Pezzetti F, Graziano A, Riccardo D, Zollino I, Brunelli G . Comparison between osteoblasts derived from human dental pulp stem cells and osteosarcoma cell lines. Cell Biol Int. 2008; 32(7):733-8. DOI: 10.1016/j.cellbi.2008.02.003. View

Tominaga E, Yuasa K, Shimazaki S, Hijikata T . MicroRNA-1 targets Slug and endows lung cancer A549 cells with epithelial and anti-tumorigenic properties. Exp Cell Res. 2012; 319(3):77-88. DOI: 10.1016/j.yexcr.2012.10.015. View

Novello C, Pazzaglia L, Cingolani C, Conti A, Quattrini I, Manara M . miRNA expression profile in human osteosarcoma: role of miR-1 and miR-133b in proliferation and cell cycle control. Int J Oncol. 2012; 42(2):667-75. DOI: 10.3892/ijo.2012.1717. View

Reid J, Sokolova V, Zoni E, Lampis A, Pizzamiglio S, Bertan C . miRNA profiling in colorectal cancer highlights miR-1 involvement in MET-dependent proliferation. Mol Cancer Res. 2012; 10(4):504-15. DOI: 10.1158/1541-7786.MCR-11-0342. View

Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y . Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol. 2010; 28(10):1721-6. DOI: 10.1200/JCO.2009.24.9342. View

10.

Fleming J, Gable D, Samadzadeh-Tarighat S, Cheng L, Yu L, Gillespie J . Differential expression of miR-1, a putative tumor suppressing microRNA, in cancer resistant and cancer susceptible mice. PeerJ. 2013; 1:e68. PMC: 3642704. DOI: 10.7717/peerj.68. View

11.

DeLaney T, Duan Z, Hornicek F . Proteomic profiling of chordoma. J Surg Oncol. 2010; 102(7):719. DOI: 10.1002/jso.21766. View

12.

Nasser M, Datta J, Nuovo G, Kutay H, Motiwala T, Majumder S . Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J Biol Chem. 2008; 283(48):33394-405. PMC: 2586284. DOI: 10.1074/jbc.M804788200. View

13.

Holleman A, Chung I, Olsen R, Kwak B, Mizokami A, Saijo N . miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo. Oncogene. 2011; 30(43):4386-98. PMC: 3572709. DOI: 10.1038/onc.2011.148. View

14.

Yang C, Schwab J, Schoenfeld A, Hornicek F, Wood K, Nielsen G . A novel target for treatment of chordoma: signal transducers and activators of transcription 3. Mol Cancer Ther. 2009; 8(9):2597-605. DOI: 10.1158/1535-7163.MCT-09-0504. View

15.

Zhang L, Guo S, Schwab J, Nielsen G, Choy E, Ye S . Tissue microarray immunohistochemical detection of brachyury is not a prognostic indicator in chordoma. PLoS One. 2013; 8(9):e75851. PMC: 3781148. DOI: 10.1371/journal.pone.0075851. View

16.

Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G . Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012; 12(2):89-103. DOI: 10.1038/nrc3205. View

17.

Yan D, Dong X, Chen X, Wang L, Lu C, Wang J . MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development. J Biol Chem. 2009; 284(43):29596-604. PMC: 2785592. DOI: 10.1074/jbc.M109.020511. View

18.

Kobayashi E, Hornicek F, Duan Z . MicroRNA Involvement in Osteosarcoma. Sarcoma. 2012; 2012:359739. PMC: 3329862. DOI: 10.1155/2012/359739. View

19.

Migliore C, Martin V, Leoni V, Restivo A, Atzori L, Petrelli A . MiR-1 downregulation cooperates with MACC1 in promoting MET overexpression in human colon cancer. Clin Cancer Res. 2011; 18(3):737-47. DOI: 10.1158/1078-0432.CCR-11-1699. View

20.

Duan Z, Choy E, Harmon D, Liu X, Susa M, Mankin H . MicroRNA-199a-3p is downregulated in human osteosarcoma and regulates cell proliferation and migration. Mol Cancer Ther. 2011; 10(8):1337-45. PMC: 3711153. DOI: 10.1158/1535-7163.MCT-11-0096. View